Top worldwide anti-diabetic products by market share 2017 and 2024

This statistic displays the market share of top anti-diabetic products worldwide in 2017 and a projection for 2024. Novo Nordisk's Ozempic is expected to have a market share of 7.4 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.

Top anti-diabetic products worldwide based on market share in 2017 and 2024

Product (Company)20172024
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

Market share based on revenue.
* Projected.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Diabetes"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.